Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Nutr Metab Cardiovasc Dis ; 31(2): 691-698, 2021 02 08.
Article in English | MEDLINE | ID: mdl-33131992

ABSTRACT

BACKGROUND AND AIMS: The oral administration of insulin has so far been precluded by gastro-intestinal enzyme degradation and poor intestinal absorption. Preliminary evidence for peptide uptake by the gut has recently been obtained, by our research group, following the administration of nanostructured lipid-carrier suspensions loaded with glargine insulin in healthy animal models. METHODS AND RESULTS: In this experimental study, glargine insulin-loaded nanostructured lipid carriers have been converted into solid oral dosage forms (tablets, capsules), that are more suitable for administration in humans and have prolonged shelf-life. The liquid and solid oral dosage forms were tested for glargine insulin uptake and glucose responsivity in healthy and streptozotocin-induced diabetic rats (6 animals in each group). A suitable composition gave redispersible solid oral dosage forms from glargine insulin-loaded carriers, using both spray-drying and freeze-drying. It was observed that the liquid and solid formulations had relevant hypoglycaemic effects in healthy rats, while only capsules were efficacious in diabetic rats; probably because of gut alterations in these animal models. Detected glargine insulinaemia was consistent with a glycaemic profile. CONCLUSION: The formulations under study showed their potential as oral glucose-lowering agents, particularly when used as capsules. However, further study is needed to produce a useful orally-active insulin preparation.


Subject(s)
Blood Glucose/drug effects , Drug Carriers , Hypoglycemic Agents/administration & dosage , Insulin Glargine/administration & dosage , Lipids/chemistry , Nanoparticles , Administration, Oral , Animals , Biomarkers/blood , Blood Glucose/metabolism , Capsules , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/drug therapy , Drug Compounding , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/pharmacokinetics , Insulin Glargine/chemistry , Insulin Glargine/pharmacokinetics , Male , Pharmaceutical Solutions , Rats, Wistar , Streptozocin , Tablets
2.
Comp Med ; 67(2): 147-156, 2017 Mar 01.
Article in English | MEDLINE | ID: mdl-28381315

ABSTRACT

Research in neurooncology traditionally requires appropriate in vivo animal models, on which therapeutic strategies are tested before human trials are designed and proceed. Several reproducible animal experimental models, in which human physiologic conditions can be mimicked, are available for studying glioblastoma multiforme. In an ideal rat model, the tumor is of glial origin, grows in predictable and reproducible patterns, closely resembles human gliomas histopathologically, and is weakly or nonimmunogenic. In the current study, we used MRI and histopathologic evaluation to compare the most widely used allogeneic rat glioma model, C6-Wistar, with the F98-Fischer syngeneic rat glioma model in terms of percentage tumor growth or regression and growth rate. In vivo MRI demonstrated considerable variation in tumor volume and frequency between the 2 rat models despite the same stereotactic implantation technique. Faster and more reproducible glioma growth occurred in the immunoresponsive environment of the F98-Fischer model, because the immune response is minimized toward syngeneic cells. The marked inability of the C6-Wistar allogeneic system to generate a reproducible model and the episodes of spontaneous tumor regression with this system may have been due to the increased humoral and cellular immune responses after tumor implantation.


Subject(s)
Disease Models, Animal , Glioma/pathology , Rats/immunology , Allografts/immunology , Allografts/pathology , Animals , Glioma/immunology , Isografts/immunology , Isografts/pathology , Magnetic Resonance Imaging/veterinary , Rats/genetics , Rats, Inbred F344/genetics , Rats, Inbred F344/immunology , Rats, Wistar/genetics , Rats, Wistar/immunology , Reproducibility of Results
3.
J Feline Med Surg ; 11(10): 869-72, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19464217

ABSTRACT

A 12-year-old male cat was referred for progressive limb weakness lasting 2 weeks. Physical examination detected muscle atrophy and bilateral renomegaly with distortion of the renal contours. The cat was ambulatory but tetraparetic. It showed a peculiar posture on forelimbs with bilateral flexion of the carpi and extrarotation of forearms. The cat was unable to go upstairs or jump. Neurological examination showed findings compatible with peripheral nervous system involvement. Histopathological findings revealed a high grade non-B, non-T cell renal lymphoma and peripheral neuropathy characterised by demyelination, axonal degeneration and muscle denervation. In the absence of congenital, metabolic and infectious diseases or exposure to toxins, a paraneoplastic peripheral neuropathy was hypothesised. In humans and dogs, paraneoplastic peripheral neuropathies have been documented with different neoplastic processes including lymphoproliferative disorders. To the authors' knowledge, this is the first report of suspected paraneoplastic polyneuropathy in a cat with malignant tumour.


Subject(s)
Cat Diseases/etiology , Lymphoma, Non-Hodgkin/veterinary , Paraneoplastic Polyneuropathy/veterinary , Peripheral Nervous System Diseases/veterinary , Animals , Antineoplastic Agents, Hormonal/administration & dosage , Cat Diseases/diagnosis , Cat Diseases/drug therapy , Cat Diseases/pathology , Cats , Euthanasia, Animal , Kidney Neoplasms/complications , Kidney Neoplasms/diagnosis , Kidney Neoplasms/pathology , Kidney Neoplasms/veterinary , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/pathology , Male , Paraneoplastic Polyneuropathy/diagnosis , Paraneoplastic Polyneuropathy/etiology , Peripheral Nervous System Diseases/diagnosis , Peripheral Nervous System Diseases/etiology , Prednisone/administration & dosage
5.
J Feline Med Surg ; 8(5): 340-4, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16651017

ABSTRACT

This report describes an uncommon clinical case of cystic parathyroid adenocarcinoma. A 17-year-old male Persian cat was presented for evaluation of a ventral cervical mass. The cat was inappetent and showed weight loss, polydipsia and vomiting. Serum biochemistry and urinalysis revealed moderate hypercalcaemia, a mild increase of creatinine, isosthenuria and proteinuria. Sodium dodecyl sulphate-agarose gel electrophoresis showed a mixed tubular proteinuric pattern, in accordance with histological examination that revealed interstitial nephritis and glomerulonephritis. Diagnosis of parathyroid carcinoma was based on histopathological findings.


Subject(s)
Adenocarcinoma/veterinary , Cat Diseases/pathology , Parathyroid Neoplasms/veterinary , Adenocarcinoma/pathology , Animals , Autopsy/veterinary , Cat Diseases/surgery , Cats , Cysts/veterinary , Male , Parathyroid Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...